Table of Contents 
ISRN Cardiology
Volume 2012, Article ID 745185, 11 pages
http://dx.doi.org/10.5402/2012/745185
Research Article

Doxorubicin and NRG-1/erbB4-Deficiency Affect Gene Expression Profile: Involving Protein Homeostasis in Mouse

Cecilia Vasti,1 Henning Witt,2 Matilde Said,3 Patricia Sorroche,4 Hernán García-Rivello,4 Patricia Ruiz-Noppinger,2 and Cecilia M. Hertig1

1Instituto de Investigaciones en Ingeniería Genética y Biología Molecular—(INGEBI), Vuelta de Obligado 2490, Buenos Aires 1428, Argentina
2Center for Cardiovascular Research, Charité Universitätsmedizin Berlin, Hessische Strasse 3-4, 10115 Berlin, Germany
3Centro de Investigaciones Cardiovasculares, Facultad de Medicina, Universidad de La Plata, Diagonal 120 y Av. 60, 1900 La Plata, Argentina
4Hospital Italiano Buenos Aires, Servicio de Anatomía Patológica y Laboratorio, Gascón 450, 1181 Buenos Aires, Argentina

Received 16 April 2012; Accepted 1 July 2012

Academic Editors: G. Moe and T. Shioi

Copyright © 2012 Cecilia Vasti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Baselga, “New horizons: gene therapy for cancer,” Anti-Cancer Drugs, vol. 10, supplement 1, pp. S39–S42, 1999. View at Google Scholar · View at Scopus
  2. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer,” New England Journal of Medicine, vol. 353, no. 16, pp. 1673–1684, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Özcelik, B. Erdmann, B. Pilz et al., “Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 13, pp. 8880–8885, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. S. A. Crone, Y. Y. Zhao, L. Fan et al., “ErbB2 is essential in the prevention of dilated cardiomyopathy,” Nature Medicine, vol. 8, no. 5, pp. 459–465, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. H. García-Rivello, J. Taranda, M. Said et al., “Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 289, no. 3, pp. H1153–H1160, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Sadzuka, T. Sugiyama, K. Shimoi, N. Kinae, and S. Hirota, “Protective effect of flavonoids on doxorubicin-induced cardiotoxicity,” Toxicology Letters, vol. 92, no. 1, pp. 1–7, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. H. C. Lai, Y. C. Yeh, C. T. Ting et al., “Doxycycline suppresses doxorubicin-induced oxidative stress and cellular apoptosis in mouse hearts,” European Journal of Pharmacology, vol. 644, no. 1–3, pp. 176–187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Said, R. Becerra, C. A. Valverde et al., “Calcium-calmodulin dependent protein kinaseII (CaMKII: a main signal responsible for early reperfusion arrhythmias,” Journal of Molecular and Cellular Cardiology, vol. 51, no. 6, pp. 936–944, 2011. View at Publisher · View at Google Scholar
  10. V. G. Tusher, R. Tibshirani, and G. Chu, “Significance analysis of microarrays applied to the ionizing radiation response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5116–5121, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Wellner, R. Dechend, J. K. Park et al., “Cardiac gene expression profile in rats with terminal heart failure and cachexia,” Physiological Genomics, vol. 20, pp. 256–267, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Zhao, A. Chow, J. Powers, G. Fajardo, and D. Bernstein, “Microarray analysis of gene expression after transverse aortic constriction in mice,” Physiological Genomics, vol. 19, pp. 93–105, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. S. W. Kong, N. Bodyak, P. Yue et al., “Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats,” Physiological Genomics, vol. 21, pp. 34–42, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Ashburner, C. A. Ball, J. A. Blake et al., “Gene ontology: tool for the unification of biology,” Nature Genetics, vol. 25, no. 1, pp. 25–29, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Jiang, B. Zhang, P. Liang et al., “Nucleolin/C23 mediates the antiapoptotic effect of heat shock protein 70 during oxidative stress,” FEBS Journal, vol. 277, no. 3, pp. 642–652, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Koch, K. Savvatis, M. Scheeler et al., “Immunosuppression with an interleukin-2 fusion protein leads to improved LV function in experimental ischemic cardiomyopathy,” International Immunopharmacology, vol. 10, no. 2, pp. 207–212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Ushikoshi, T. Takahashi, X. Chen et al., “Local overexpression of HB-EGF exacerbates remodeling following myocardial infarction by activating noncardiomyocytes,” Laboratory Investigation, vol. 85, no. 7, pp. 862–873, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Asakura, M. Kitakaze, S. Takashima et al., “Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy,” Nature Medicine, vol. 8, no. 1, pp. 35–40, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. J. R. McMullen, T. Shioi, W. Y. Huang et al., “The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110α) pathway,” Journal of Biological Chemistry, vol. 279, no. 6, pp. 4782–4793, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. P. C. Schulze, J. Fang, K. A. Kassik et al., “Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction,” Circulation Research, vol. 97, no. 5, pp. 418–426, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Mukhopadhyay, M. Rajesh, S. Bátkai et al., “Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 296, no. 5, pp. H1466–H1483, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. T. J. Schulz, D. Westermann, F. Isken et al., “Activation of mitochondrial energy metabolism protects against cardiac failure.,” Aging, vol. 2, no. 11, pp. 843–853, 2010. View at Google Scholar · View at Scopus
  23. C. M. Hertig, S. W. Kubalak, Y. Wang, and K. R. Chien, “Synergistic roles of neuregulin-1 and insulin-like growth factor-I in activation of the phosphatidylinositol 3-kinase pathway and cardiac chamber morphogenesis,” Journal of Biological Chemistry, vol. 274, no. 52, pp. 37362–37369, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. F. F. Liu, J. R. Stone, A. J. T. Schuldt et al., “Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 289, no. 2, pp. H660–H666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. H. El Azzouzi, S. Leptidis, M. Bourajjaj et al., “Peroxisome proliferator-activated receptor (PPAR) gene profiling uncovers insulin-like growth factor-1 as a PPARα target gene in cardioprotection,” Journal of Biological Chemistry, vol. 286, no. 16, pp. 14598–14607, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Yoshida, L. Semprun-Prieto, S. Sukhanov, and P. Delafontaine, “IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 298, no. 5, pp. H1565–H1570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Yamamoto, Y. Hoshino, T. Ito et al., “Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes,” Cardiovascular Research, vol. 79, no. 1, pp. 89–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. S. Willis, W. H. D. Townley-Tilson, E. Y. Kang, J. W. Homeister, and C. Patterson, “Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease,” Circulation Research, vol. 106, no. 3, pp. 463–478, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Dhesi, F. Tehrani, J. Fuess, and E. R. Schwarz, “How does the heart (not) die? The role of autophagy in cardiomyocyte homeostasis and cell death,” Heart Failure Reviews, vol. 15, no. 1, pp. 15–21, 2010. View at Google Scholar · View at Scopus
  30. S. Schlossarek and L. Carrier, “The ubiquitin-proteasome system in cardiomyopathies,” Current Opinion in Cardiology, vol. 26, no. 3, pp. 190–195, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Kostin, L. Pool, A. Elsässer et al., “Myocytes die by multiple mechanisms in failing human hearts,” Circulation Research, vol. 92, no. 7, pp. 715–724, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Galluzzi, I. Vitale, J. M. Abrams et al., “Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death,” Cell Death and Differentiation, vol. 19, no. 1, pp. 107–120, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. C. A. Vigliano, P. M. Cabeza Meckert, M. Diez et al., “Cardiomyocyte hypertrophy, oncosis, and autophagic vacuolization predict mortality in idiopathic dilated cardiomyopathy with advanced heart failure,” Journal of the American College of Cardiology, vol. 57, no. 14, pp. 1523–1531, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Cardinale, A. Colombo, R. Torrisi et al., “Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation,” Journal of Clinical Oncology, vol. 28, no. 25, pp. 3910–3916, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Sawaya, I. A. Sebag, J. C. Plana et al., “Early detection and prediction of cardiotoxicity in chemotherapy-treated patients,” American Journal of Cardiology, vol. 107, no. 9, pp. 1375–1380, 2011. View at Publisher · View at Google Scholar · View at Scopus